Are peptides legal in the US? Where things stand in October 2026
It depends on the peptide and how it reaches you. FDA-approved peptide drugs are legal with a prescription. Compounded peptides are legal only when the ingredient is eligible for compounding, and in 2026 the list of eligible peptides has been moving. Products sold online as “for research use only” are a separate category again. This is a description of where things stand, not legal advice.
Approved peptide drugs
Semaglutide, tirzepatide, tesamorelin, bremelanotide (PT-141) and elamipretide (SS-31) are FDA-approved for specific uses and are legal with a prescription for those products. Retatrutide is not approved; its maker plans to file in early 2027 (see the TRIUMPH results).
Compounded peptides
A compounding pharmacy can only make a medicine from an ingredient that is eligible. In 2023 the FDA had placed BPC-157, TB-500 and other peptides on a list of ingredients that raise “significant safety concerns”, which in practice stopped pharmacies from compounding them. This year:
- April 15, 2026: the FDA said it would take twelve peptides off that list. That did not, on its own, make any of them eligible.
- July 23–24, 2026: the FDA’s Pharmacy Compounding Advisory Committee narrowly recommended six of them for the eligible list (BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax) and declined the seventh, emideltide (DSIP). FDA staff scientists had opposed all seven. The vote is advice, not a decision.
- October 15, 2026: HHS sent an interim access policy to the White House that would let pharmacies compound some peptides temporarily while permanent rules are written (details).
- Still pending: five more peptides, including injectable GHK-Cu and Melanotan-II, are due for committee review before February 2027.
Making the six eligible for good requires FDA rulemaking with public comment, which can take a year or more.
“Research use only”
Many online sellers label peptides “for research use only, not for human consumption”. That label describes how a product is sold. It is not an FDA approval, and it does not make a product a compounded medicine.
State law
States regulate pharmacies, prescribing and who may administer compounded medicines, and the rules differ. A federal change does not override them.
Sources
- JD Supra (Goodwin) — FDA signals potentially evolving stance toward compounding of certain peptides
- ABC News — FDA advisers narrowly vote to add 6 peptides to a drug compounding list (Jul 24, 2026)
- AJMC — Peptide regulation debate intensifies after FDA advisory panel’s controversial vote
- STAT — Trump administration advances plan for peptide drugs favored by RFK Jr. (Oct 15, 2026)
- FDA — FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list (Apr 30, 2026)